TRANSMEDICS (TMDX) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action

Philadelphia, Pennsylvania--(Newsfile Corp. - March 13, 2025) - A securities class action lawsuit has been filed against TRANSMEDICS GROUP, INC. ("TransMedics" or the "Company") (NASDAQ: TMDX). The lawsuit has been filed on behalf of purchasers of TransMedics securities between February 28, 2023 and January 10, 2025, inclusive (the "Class Period").

CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT.

Investors who purchased or acquired TRANSMEDICS securities during the Class Period may, no later than APRIL 15, 2025, seek to be appointed as a lead plaintiff representative of the class.

According to the lawsuit, throughout the Class Period, the Company and its senior executives misled investors and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics concealed safety issues and a lack of safety oversight within the organization.

Investors learned the truth about TransMedics on February 21, 2024, when U.S. Rep. Paul Gosar sent a letter to the Company accusing it of, among other things, misappropriating corporate resources and gouging transplant centers. On this news, the price of TransMedics stock fell $2.18 per share, or 2.5%, to a close of $84.81 per share on February 22, 2024.

Then, on January 10, 2025, Scorpion Capital issued a report accusing TransMedics of, among other things, overbilling hospitals and providing patients with organs that had been rejected by reputable physicians. According to the action, on this news, TransMedics shares fell $3.74 per share, or 5%, to a closing price of $68.81 on January 10, 2025, and another $4.76 per share (6.9%) on January 13, 2025, to close at $64.05 per share.

For additional information or to learn how to participate in this litigation, please contact Berger Montague: Andrew Abramowitz at [e-mail] or [phone], or Peter Hamner at [e-mail], or CLICK HERE.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contact:

Andrew Abramowitz, Senior Counsel
Berger Montague
[phone]
[e-mail]

Peter Hamner
Berger Montague PC
[e-mail]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244397

The TransMedics Group Stock at the time of publication of the news with a raise of +0,72 % to 61,92EUR on Tradegate stock exchange (13. März 2025, 13:27 Uhr).